Sensus Hlthcr
Stock
Stock
ISIN: US81728J1097
Ticker: SRTS
US81728J1097
SRTS
Price
Price
CHART BY
Frequently asked questions
What is Sensus Hlthcr's market capitalization?
The market capitalization of Sensus Hlthcr is $88.18M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Sensus Hlthcr's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Sensus Hlthcr is 13.24. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Sensus Hlthcr?
Sensus Hlthcr's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.407. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Sensus Hlthcr's stock?
Currently, 5 analysts cover Sensus Hlthcr's stock, with a consensus target price of $13.00. Analyst ratings provide insights into the stock's expected performance.
What is Sensus Hlthcr's revenue over the trailing twelve months?
Over the trailing twelve months, Sensus Hlthcr reported a revenue of $41.81M.
What is the EBITDA for Sensus Hlthcr?
Sensus Hlthcr's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $8.47M. EBITDA measures the company's overall financial performance.
What is the free float of Sensus Hlthcr's shares?
The free float of Sensus Hlthcr is 13.46M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $88.18M
- EPS (TTM)
- $0.407
- Free Float
- 13.46M
- P/E ratio (TTM)
- 13.24
- Revenue (TTM)
- $41.81M
- EBITDA (TTM)
- $8.47M
Pricing
- 1D span
- $5.362$5.661
- 52W span
- $2.92$9.32
Analyst Ratings
The price target is $13.00 and the stock is covered by 5 analysts.
Buy
5
Hold
0
Sell
0
Information
Sensus Healthcare, Inc. is a medical device company, which engages in the provision of treatment for both oncological and non-oncological skin conditions. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.
- Industries
- Medical Specialties
- Sector
- Health Care
Identifier
- ISIN
- US81728J1097
- Primary Ticker
- SRTS
Knockouts
Finance data from FactSet